Neurogene Inc expected to post a loss of $1.17 a share - Earnings Preview

Neurogene

15/03/2024 20:29

* Neurogene Inc  NGNE.OQ   NGNE.O  is expected to show no
change
in quarterly revenue when it reports  results on March 18
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Neurogene Inc is for a
loss of
$1.17 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Neurogene
Inc is
$44.50​, above​ its last closing price of $34.56. ​​​

This summary was machine generated March 15 at 20:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)